STOCK TITAN

X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
conferences earnings

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) will report first-quarter 2024 financial results on May 7, 2024, and host a conference call and webcast. The company focuses on rare immune system diseases, aiming to enhance patient lives.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) presenterà i risultati finanziari del primo trimestre del 2024 il 7 maggio 2024 e terrà una conferenza telefonica e un webcast. L'azienda si concentra su malattie rare del sistema immunitario, con l'obiettivo di migliorare la vita dei pazienti.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) informará sobre los resultados financieros del primer trimestre de 2024 el 7 de mayo de 2024, y realizará una llamada de conferencia y un webcast. La compañía se enfoca en enfermedades raras del sistema inmunitario, buscando mejorar la vida de los pacientes.
X4 Pharmaceuticals, Inc. (나스닥: XFOR)는 2024년 5월 7일에 2024년도 1분기 재무 결과를 보고하고 컨퍼런스 콜 및 웹캐스트를 주최할 예정입니다. 이 회사는 희귀한 면역 체계 질환에 중점을 두고 환자의 삶을 개선하고자 합니다.
X4 Pharmaceuticals, Inc. (Nasdaq : XFOR) publiera les résultats financiers du premier trimestre 2024 le 7 mai 2024, et organisera une conférence téléphonique ainsi qu'un webcast. L'entreprise se concentre sur les maladies rares du système immunitaire, dans le but d'améliorer la vie des patients.
X4 Pharmaceuticals, Inc. (Nasdaq: XFOR) wird am 7. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 bekannt geben und eine Telefonkonferenz sowie ein Webcast veranstalten. Das Unternehmen konzentriert sich auf seltene Krankheiten des Immunsystems, mit dem Ziel, das Leben der Patienten zu verbessern.
Positive
  • None.
Negative
  • None.

BOSTON, April 30, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.

The company will host a conference call and webcast on the same day at 8:30 a.m. ET. The conference call can be accessed by dialing 1-877-451-6152 from the United States or 1-201-389-0879 internationally, followed by the conference ID: 13745487. The live webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website at www.x4pharma.com. Following the completion of the call, a webcast replay will be available on the website.

About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI™ (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at www.x4pharma.com.

Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com

Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576


FAQ

When will X4 Pharmaceuticals report its first-quarter 2024 financial results?

X4 Pharmaceuticals will report its first-quarter 2024 financial results on May 7, 2024.

What is the conference call and webcast schedule for X4 Pharmaceuticals?

X4 Pharmaceuticals will host a conference call and webcast on May 7, 2024, at 8:30 a.m. ET.

How can I access the conference call and webcast for X4 Pharmaceuticals?

The conference call can be accessed by dialing 1-877-451-6152 (US) or 1-201-389-0879 (international) with the conference ID: 13745487. The webcast will be available on X4 Pharmaceuticals' investor relations website at www.x4pharma.com.

X4 Pharmaceuticals, Inc.

NASDAQ:XFOR

XFOR Rankings

XFOR Latest News

XFOR Stock Data

98.92M
155.53M
1.15%
67.66%
6.78%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOSTON